BioSpace News Archive

Through collaboration, researchers from different organizations can work together to explore, test and validate transformative research ideas that will benefit Canadians.

Ron Rodgers Joins Athletico as Chief Executive Officer; Founder Mark Kaufman Remains as Executive Chairman

PurpleStride Supports the Pancreatic Cancer Action Network’s Urgent Mission to Save Lives and Improve Patient Outcomes

Kowa Pharmaceuticals America, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved the cholesterol-lowering drug LIVALO® (pitavastatin) for pediatric patients aged 8 years and older with heterozygous familial hypercholesterolemia (HeFH) to reduce elevated total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C) and apolipoprotein B (Apo B).

Kala Pharmaceuticals, Inc., announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company’s 2017 Equity Incentive Plan in accordance with NASDAQ Listing Rule 5635.

AngioDynamics, Inc. announced that it will report financial results for the fourth quarter and fiscal year 2019 before the market open on Wednesday, July 10, 2019.

Universal Display Corporation (Nasdaq: OLED), enabling energy-efficient displays and lighting with its UniversalPHOLED® technology and materials, today held its 2019 Annual Meeting of Shareholders.

Patient needs take center stage as the companies leverage their strengths in coordinated primary, specialty, and urgent care

Tampa General Hospital is leasing up to 25,000 square feet of space in the new USF Health Morsani College of Medicine and Heart Institute building now nearing completion in downtown Tampa, creating even more synergy with the university and its primary teaching hospital.

BD, a leading global medical technology company, issued the following statement following the U.S. Food and Drug Administration Circulatory System Devices Panel of the Medical Devices Advisory Committee meeting related to the potential increase in mortality associated with the use of paclitaxel-coated devices in patients with peripheral arterial disease in the superficial femoropopliteal artery